GLP1R encodes the glucagon-like peptide-1 receptor, a G-protein coupled receptor that binds GLP-1 and activates adenylyl cyclase signaling to increase intracellular cAMP levels. This receptor plays a central role in glucose homeostasis by regulating insulin secretion from pancreatic β-cells in response to GLP-1 1. The receptor mediates multiple metabolic effects including potentiation of glucose-induced insulin secretion, inhibition of glucagon release, delayed gastric emptying, promotion of satiety, and increased peripheral glucose disposal 1. GLP1R is predominantly localized in pancreatic β-cells, with additional expression in cardiac sinoatrial node myocytes, smooth muscle cells of renal and pulmonary arteries, and gastrointestinal tract neurons 2. Disease associations include diabetes mellitus, obesity, cardiovascular disease, and metabolic syndrome. Multiple approved GLP-1 receptor agonists target this receptor, including semaglutide, liraglutide, dulaglutide, and exenatide, which are used to treat type 2 diabetes and obesity 3. Clinical studies demonstrate that genetic variants in GLP1R, such as rs6923761G→A, can influence treatment response to semaglutide in patients with severe obesity 3. Recent research suggests potential broader therapeutic applications, with evidence that GLP-1 receptor agonists may reduce binge drinking and alcohol-associated phenotypes 4, though concerns exist regarding their effects on certain neuroendocrine tumors that express GLP1R 5.